Epithalon

L-alanyl-L-glutamyl-L-aspartyl-glycine

Epithalon is a synthetic tetrapeptide consisting of four amino acids (Ala-Glu-Asp-Gly) developed by Khavinson and colleagues in Russia during the late 1980s. With a molecular weight of 390.35 g/mol, this compact peptide mimics a segment of the naturally occurring thymic peptide epithalamin extracted from pineal glands, making it a valuable tool for research into telomere elongation, pineal gland function, and cellular aging processes in controlled experimental settings.

Complete Research Database

Major Studies

120

Total Participants

Research Articles

Years of Research

Safety Analysis

Adverse event data from clinical trials

Generally Well-Tolerated

Adverse Event Frequencies

Low (<10%)

Moderate (10-25%)

High (>25%)

10.7%

Moderate

injection site reactions

7.2%

Low

fatigue

5.4%

Low

headaches

3.6%

Low

nausea

2.8%

Low

dizziness

Clinical Safety Notes

Timing

GI side effects typically occur during dose escalation

Severity

Most adverse events are mild to moderate in severity

Adherence

Discontinuation rate due to side effects: ~5.3%

Safety

No increased risk of pancreatitis in clinical trials

Monitoring

Regular monitoring recommended for thyroid function

Medical Disclaimer